COVID-19: Vaccines and Therapeutics
The Department of Health and Human Services’ Biomedical Advanced Research and Development Authority issued a $265 million task order reserving vaccine manufacturing capacity through December 2021 at an advanced manufacturing center in Texas.
Atrium Health President and CEO Eugene Woods spoke on CBS’s Face the Nation about the lack of reagents for COVID-19 testing, racial disparities during the pandemic and treating thousands of COVID-19 patients in their homes.
The National Institutes of Health announced that a COVID-19 vaccine candidate co-developed by Moderna, Inc. and the National Institute of Allergy and Infectious Diseases has begun a phase 3 clinical trial.
The National Academies of Sciences, Engineering, and Medicine and the National Academy of Medicine July 24 will host its inaugural committee meeting on the equitable allocation of a COVID-19 vaccine.
The Department of Health and Humans Services said it has an agreement with Pfizer to produce and deliver 100 million doses of the drug maker’s COVID-19 vaccine candidate.
A COVID-19 trial vaccine developed by the University of Oxford and AstraZeneca produced neutralizing antibody responses in patients with SARS-CoV-2, according to a study published July 20 in The Lancet.
The first human study evaluating an mRNA COVID-19 vaccine made by Moderna Inc. produced neutralizing antibodies in healthy adults, who generally tolerated the vaccine well, the National Institutes of Health reports.
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune globulin product, it was announced.
The Department of Health and Human Services and Department of Defense announced a $1.6 billion agreement to demonstrate commercial-scale manufacturing of Novavax, Inc.’s investigational COVID-19 vaccine.
The Food and Drug Administration issued guidance for the development of a SARS-CoV-2 vaccine, outlining key considerations to satisfy requirements for chemistry, manufacturing and control, nonclinical and clinical data.